Minerva Neurosciences Reports Second Quarter 2019 Financial Results and Business Updates
Minerva Neurosciences, Inc (NERV)
Last minerva neurosciences, inc earnings: 3/9 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.minervaneurosciences.com/investor-relations
Company Research
Source: GlobeNewswire
During the Second Quarter, Minerva announced several important clinical advancements, including positive top line results from two Phase 2b studies of seltorexant (MIN-202) in major depressive disorder (MDD) and insomnia Patient enrollment progresses in pivotal Phase 3 trial of roluperidone (MIN-101) in schizophrenia, Phase 2 trial of seltorexant in MDD and Phase 2b trial of MIN-117 in MDD WALTHAM, Mass., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the quarter ended June 30, 2019. “In the first half of 2019, we presented positive data from two Phase 2b clinical trials with seltorexant,” said Dr. Remy Luthringer, Executive Chairman and Chief Executive Officer of Minerva. “In addition, in a recent biomarker study with seltorexant, we demonstrated mood impro
Show less
Read more
Impact Snapshot
Event Time:
NERV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NERV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NERV alerts
High impacting Minerva Neurosciences, Inc news events
Weekly update
A roundup of the hottest topics
NERV
News
- Minerva Neurosciences, Inc. (NASDAQ: NERV) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Minerva Neurosciences, Inc. (NASDAQ: NERV) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Minerva Neurosciences, Inc. (NASDAQ: NERV) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.MarketBeat
- Minerva Neurosciences GAAP EPS of $2.97 Nov. 05, 2024 7:37 AM ET By: Deepa Sarvaiya , SA News Editor [Seeking Alpha]Seeking Alpha
- Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business UpdatesGlobeNewswire
NERV
Earnings
- 11/5/24 - Beat
NERV
Analyst Actions
- 11/6/24 - HC Wainwright
NERV
Sec Filings
- 11/12/24 - Form SC
- 11/5/24 - Form 10-Q
- 10/22/24 - Form ARS
- NERV's page on the SEC website